“质量源于设计”在制备<i>N</i>-乙酰半胱氨酸注射液中的应用

张莉燕; 宋金春; 张莉燕; 宋金春

doi:10.3969/j.issn.1006-0111.2019.06.016

[1]

FDA.Pharmaceutical cGMPs for the 21st Century-A Risk Based Approach[EB/OL].US,2004,[2019-02-22].https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm128080.htm.

[2]

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use(ICH).Harmonized Tripartite Guideline,Q8,Pharmaceutical Development,Current Step 4 Version[EB/OL].US,2004(2009-08).[2019-02-22].https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf.

[3]

陈柽,李冰韶,王永洁,等.设计空间法优化红花温浸提取工艺[J].中草药,2018,49(19):4544-4551.

[4]

ARAKAWA M,ITO Y.N-acetylcysteine and neurodegenerative diseases:basic and clinical pharmacology[J].Cerebellum,2007,6(4):308-314.

[5]

GREEN J L,HEARD K J,REYNOLDS K M,et al.Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity:a systematic review and meta-analysis[J].West J Emerg Med,2013,14(3):218-226.

[6]

BAVARSAD SHAHRIPOUR R,HARRIGAN M R,ALEXANDROV A V.N-acetylcysteine (NAC) in neurological disorders:mechanisms of action and therapeutic opportunities[J].Brain Behav,2014,4(2):108-122.

[7]

MINARINI A,FERRARI S,GALLETTI M,et al.N-acetylcysteine in the treatment of psychiatric disorders:current status and future prospects[J].Expert Opin Drug Metab Toxicol,2017,13(3):279-292.

[8]

蒋煜,杨建红,王亚敏."质量源于设计"在仿制注射剂处方工艺研究中的应用[J].中国新药杂志,2014,23(8):921-924,954.

[9]

崔向龙,徐冰,孙飞,等.质量源于设计在银杏叶片制粒工艺中的应用(III):基于设计空间的过程控制策略[J].中国中药杂志,2017,42(6):1048-1054.